SR-3306 | 1128096-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: SR-3306
• 英文别名: N-[4-[3-(6-methylpyridin-3-yl)-1,2,4-triazol-1-yl]phenyl]-4-(3-morpholin-4-ylphenyl)pyrimidin-2-amine
• CAS: 1128096-91-2
• 化学式: C₂₈H₂₆N₈O
• 分子量: 490.567
• InChiKey: QDMXVKKPYBGIAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  93.9
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRIMIDINYL-AMINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE LA PROTÉINE KINASE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2009032861A1

  公开（公告）日：2009-03-12

  The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.

  本发明提供了一种新型的取代嘧啶基胺，可用作蛋白激酶抑制剂，特别是c-Jun N-末端激酶（JNK）的抑制剂，以及包含它们的药物组合物和使用相同的方法来治疗对JNK途径抑制敏感的疾病。
• SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS
  申请人：Kamenecka Theodore Mark

  公开号：US20130231336A1

  公开（公告）日：2013-09-05

  The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.

  本发明提供了一种新型的取代嘧啶基胺，可用作蛋白激酶抑制剂，特别是c-Jun N末端激酶（JNK）的抑制剂，以及其药物组合物和使用同样治疗对JNK通路抑制有响应的疾病的方法。
• SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20210069230A1

  公开（公告）日：2021-03-11

  The present disclosure relates to discovery of specific synergistic drug combinations and mechanisms of drug resistance. Compositions involving newly-identified drug combinations as well as diagnostic and therapeutic methods related to such discoveries are provided.
• COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME
  申请人：Hurt Clarence

  公开号：US20210324031A1

  公开（公告）日：2021-10-21

  Novel leptin and leptin-fusion protein-small molecule drug conjugates are disclosed, where conjugation takes place through the use of cleavable and non-cleavable linkers. The small molecules chemically linked to the protein carrier are imported into the specific leptin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug then act to modify leptin receptor-triggered biochemical pathways that are altered in conditions of leptin-resistance. Drug will correct altered pathway allowing resensitization of receptor signaling. This can greatly aid in the resolution of pathologies either initiated at the onset of leptin resistance or exacerbated by it.
• US8530480B2
  申请人：——

  公开号：US8530480B2

  公开（公告）日：2013-09-10